HomeANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
Previous close
$0.00020
Market cap
30.00 USD
Avg Volume
11.64K
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | 2017info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 7.94M | -28.30% |
Net income | -26.87M | 51.60% |
Net profit margin | — | — |
Earnings per share | -3.80 | 70.53% |
EBITDA | -36.15M | 36.48% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | 2017info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.20M | -89.46% |
Total assets | 3.67M | -84.35% |
Total liabilities | 9.17M | -13.70% |
Total equity | -5.50M | — |
Shares outstanding | 23.40M | — |
Price to book | -0.00 | — |
Return on assets | -167.77% | — |
Return on capital | -619.42% | — |
Cash Flow
Net change in cash
| (USD) | 2017info | Y/Y change |
|---|---|---|
Net income | -26.87M | 51.60% |
Cash from operations | -36.90M | 24.57% |
Cash from investing | — | — |
Cash from financing | 18.25M | -22.58% |
Net change in cash | -18.65M | 28.58% |
Free cash flow | -23.15M | 18.17% |
About
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Founded
2004
Headquarters
Website
Employees
21
